Cerus Corp (CERS) Reports INTERCEPT Blood System Phase 2 Met Primary Endpoint
Tweet Send to a Friend
Cerus Corp (NASDAQ: CERS) announced that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE